Alaunos Therapeutics, Inc. (TCRT) Operating income 2016–2025
Alaunos Therapeutics, Inc. (TCRT) annual operating income history from SEC filings — each fiscal year as reported.
-$4.2MFY2025 · since FY2016: -$165.3M → -$4.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$4.2M | +12.2% |
| FY2024 | -$4.8M | +86.0% |
| FY2023 | -$34.3M | +2.4% |
| FY2022 | -$35.1M | +54.7% |
| FY2021 | -$77.5M | +3.5% |
| FY2020 | -$80.4M | -38.9% |
| FY2019 | -$57.9M | -7.3% |
| FY2018 | -$53.9M | -0.8% |
| FY2017 | -$53.5M | +67.6% |
| FY2016 | -$165.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TCRT financial trends
TCRT RevenueTCRT Net incomeTCRT Net marginTCRT Gross profitTCRT Gross marginTCRT Operating marginTCRT Operating cash flowTCRT Free cash flowTCRT Capital expendituresTCRT Return on equityTCRT Stock buybacksTCRT Dividends paidTCRT Total assetsTCRT Total liabilitiesTCRT Shareholders’ equityTCRT overview →